STOCK TITAN
  1. Home
  2. Sec-filings
  3. NERV
  4. [8-K] Minerva Neurosciences, Inc. Reports Material Event

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. appointed Anthony Aliquo, previously Vice President, Controller, as Chief Accounting Officer and principal accounting officer, effective August 10, 2026. On the same date, Chief Financial Officer Frederick Ahlholm ceased serving as principal accounting officer but continues as CFO and principal financial officer.

Aliquo, age 39, has held successive accounting roles at Minerva since 2020 and previously worked as an auditor at BDO USA, P.C. and Deloitte & Touche, LLP. In connection with his promotion, the Board increased his annual base salary to $296,696, effective July 1, 2026, and raised his annual performance bonus target to 35% of base salary, with other compensation arrangements unchanged. The company states there are no special appointment arrangements, no family relationships with directors or executive officers, and no related-party transactions requiring disclosure.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Annual base salary $296,696 Anthony Aliquo’s base salary effective July 1, 2026
Bonus target 35% of annual base salary Anthony Aliquo’s annual performance bonus target after promotion
Age of new CAO 39 Age of Anthony Aliquo at the time of appointment
Chief Accounting Officer financial
"appointed Anthony Aliquo ... as Chief Accounting Officer and principal accounting officer"
A chief accounting officer is a senior executive responsible for overseeing a company's financial records and ensuring all accounting practices are accurate and compliant with regulations. They play a key role in preparing financial reports that help investors understand the company's financial health, much like a trusted navigator guiding a ship through complex waters. Their work ensures transparency and trust in the company's financial information.
principal accounting officer financial
"appointed Anthony Aliquo ... as Chief Accounting Officer and principal accounting officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
principal financial officer financial
"Ahlholm will continue to serve as the Company’s Chief Financial Officer and principal financial officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
Item 404(a) of Regulation S-K regulatory
"no direct or indirect interest in any transaction ... pursuant to Item 404(a) of Regulation S-K"

FAQ

What executive management change did Minerva Neurosciences (NERV) announce on August 10, 2026?
Minerva Neurosciences appointed Anthony Aliquo as Chief Accounting Officer and principal accounting officer, effective August 10, 2026, while Frederick Ahlholm continues as Chief Financial Officer and principal financial officer.

What is the new base salary for Minerva Neurosciences (NERV) Chief Accounting Officer Anthony Aliquo?
The Board increased Anthony Aliquo’s annual base salary to $296,696, effective July 1, 2026. This change accompanies his promotion to Chief Accounting Officer and principal accounting officer of Minerva Neurosciences.

What bonus opportunity did Minerva Neurosciences (NERV) grant to Anthony Aliquo?
Minerva Neurosciences set Anthony Aliquo’s annual performance bonus target at 35% of his annual base salary. This enhanced bonus opportunity was approved in connection with his appointment as Chief Accounting Officer.

Will Frederick Ahlholm remain Chief Financial Officer at Minerva Neurosciences (NERV)?
Yes. Frederick Ahlholm continues as Chief Financial Officer and principal financial officer. He only ceased serving as principal accounting officer when Anthony Aliquo was appointed to that role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
NASDAQ false 0001598646 0001598646 2026-08-10 2026-08-10
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

 

 

Minerva Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-36517   26-0784194
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

1500 District Avenue, Burlington, MA 01803

(Address of principal executive offices) (Zip Code)

(617) 600-7373

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   NERV   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 10, 2026, the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) appointed Anthony Aliquo, the Company’s Vice President, Controller, as Chief Accounting Officer and principal accounting officer of the Company, effective as of that date. Effective as of the same date, Fred Ahlholm, Chief Financial Officer of the Company, ceased to serve as the Company’s principal accounting officer. Mr. Ahlholm will continue to serve as the Company’s Chief Financial Officer and principal financial officer.

Mr. Aliquo, age 39, served as Vice President, Controller for the Company from November 2022 to July 2026, as Controller from August 2021 to November 2022 and as Assistant Controller from September 2020 to August 2021. Prior to such, Mr. Aliquo served as an Auditor for BDO USA, P.C. and, before that, he served as an Auditor for Deloitte & Touche, LLP. Mr. Aliquo is a CPA with over 10 years of accounting experience. He holds a M.S. degree in Accountancy from University of North Carolina Wilmington and a B.S. degree in Mathematics from Saint Michael’s College.

In connection with Mr. Aliquo’s appointment, the Board, upon the recommendation of the Compensation Committee of the Board, approved (i) an increase in Mr. Aliquo’s annual base salary to $296,696, effective July 1, 2026, and (ii) an increase in his annual performance bonus target to 35% of Mr. Aliquo’s annual base salary. Other than the foregoing, Mr. Aliquo’s compensatory and other arrangements with the Company will continue as in effect prior to his promotion.

There are no arrangements or understandings between Mr. Aliquo and any other person pursuant to which he is being appointed as Chief Accounting Officer of the Company. Mr. Aliquo has no family relationship with any of the executive officers or directors of the Company, and he has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 12, 2026     MINERVA NEUROSCIENCES, INC.
     

/s/ Frederick Ahlholm

      Frederick Ahlholm
      Chief Financial Officer

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents